Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile infection in mice

Microbiology and Immunology

Volumn 51, Issue 12, 2007, Pages 1209-1214

  Kaur, Sukhminderjit ^a   Vaishnavi, Chetana ^a   Prasad, Kaushal Kishore ^a   Ray, Pallab ^a   Kochhar, Rakesh ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Ampicillin; Clostridium difficile; Lansoprazole

Indexed keywords

AMPICILLIN; CLOSTRIDIUM TOXIN; LANSOPRAZOLE; MYELOPEROXIDASE; PROTON PUMP; TOXIN A; TOXIN B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BAGG ALBINO MOUSE; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; EDEMA; ENZYME ACTIVITY; HISTOPATHOLOGY; INFECTION RISK; INTESTINE EPITHELIUM; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; RISK FACTOR;

CLOSTRIDIUM DIFFICILE; MUS;

EID: 37549055403     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2007.tb04016.x     Document Type: Article

References (21)

1. Bradely, P.P., Priebet, D.A., Christensen, R.D., and Rothstein, G. 1982. Measurement of cutaneous inflammation: estimation of neutrophil content with enzyme marker. J. Invest. Dermatol. 78: 206-209.
2. Brook, I., and Walker, R.I. 1986. Pathogenicity of Clostridium difficile species with other bacteria in mixed infections. J. Infect. 13: 245-253.
3. Cleary, R.K. 1998. Clostridium difficile-associated diarrhea and colitis. Dis. Colon Rectum 41: 1435-1449.
4. Dial, S., Alrasadi, K., Monoukian, C., Huang, A., and Menzies, D. 2004. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case control studies. CMAJ 171: 33-38.
5. Dial, S., Delaney, J.A.C., Barkun, A.N., and Suissa, S. 2005. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294: 2989-2995.
6. Donskey, C.J. 2004. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin. Infect. Dis. 39: 219-226.
7. Fekety, R., and Shah, A.B. 1993. Diagnosis and treatment of Clostridium difficile colitis. Am. J. Gastroenterol. 92: 739-750.
8. IMS Health National Sales Perspectives Web site. 2004. Year-end US prescription and sales information and commentary. Available at: http://www.imshealthcanada.com/ htmen/3_2_28.htm. Accessed November 21, 2005.
9. Klingensmith, M.E., Neville, L.J., Delpire, E., Wolfe, M.M., and Soybel, D.I. 1999. Gastrin-mediated effects of omeprazole on rat colon mucosa. Surgery 126: 272-278.
10. Larson, H.E., and Borriello, S.P. 1990. Quantitative study of antibiotic-induced susceptibility to Clostridium difficile enterocecitis in hamsters. Antimicrob. Agents Chemother. 34: 1348-1353.
11. Lowe, D.O., Mamdani, M.M., Kopp, A., Low, D.E., and Juurlink, D.N. 2006. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin. Infect. Dis. 43: 1272-1276.
12. Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J. 1951. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193: 265-275.
13. May, T., Mackie, R.I., and Garleb, K.A. 1995. Effect of dietary oligosaccharides on intestinal growth of and tissue damage by Clostridium difficile. Microecol. Ther. 23: 158-170.
14. Naaber, P., Mikelsaar, R.H., Salminen, S., and Mikelsaar, M. 1998. Bacterial translocation, intestinal microflora and morphological changes of intestinal mucosa in experimental models of Clostridium difficile infection. J. Med. Microbiol. 47: 591-598.
15. Neal, K.R., Scott, H.M., Slack, R.C.B., and Logan, R.F.A. 1996. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. BMJ 312: 414-415.
16. Rolfe, R.D., and Iaconis, J.P. 1983. Intestinal colonization of infant hamsters with Clostridium difficile. Infect. Immun. 42: 480-486.
17. Vaishnavi, C., Kochhar, R., Bhasin, D.K., Thapa, B.R., and Singh, K. 1999. Detection of Clostridium difficile toxin by an indigenously developed latex agglutination assay. Trop. Gastroenterol. 20: 33-35.
18. Williams, C. 2001. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract. Res. Clin. Gastroenterol. 15: 511-521.
19. Wilson, K.H., Sheagren, J.N., Freter, R., Weatherbee, L., and Lyerly, D. 1986. Gnotobiotic models for study of the microbial ecology of Clostridium difficile and Escherichia coli. J. Infect. Dis. 153: 547-551.
20. Yearsley, K.A., Gilby, L.J., Ramadas, A.V., Kubiak, E.M., Fone, D.L., and Allison, M.C. 2006. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment. Pharmacol. Ther. 24: 613-619.
21. Zedtwiz Liebensten, K., Wenisch, C., Patruta, S., Parschalk, B., Daxbock, F., and Graninger, W. 2002. Omeprazole treatment diminishes intra- and extra-cellular neutrophil reactive oxygen production and bactericidal activity. Crit. Care Med. 30: 1118-1122.